Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study
Conclusions HCV reactivation occurred in 23% of HCV‐infected patients receiving cancer treatment, and most had an unremarkable clinical course. However, reactivation can affect the cancer treatment plan. Our findings suggest that HCV infection should not contraindicate cancer therapy and infected patients should have access to multiple cancer treatments with close monitoring while receiving regimens associated with HCV reactivation. This article is protected by copyright. All rights reserved.
Source: Hepatology - Category: Internal Medicine Authors: Harrys A. Torres, Jeff Hosry, Parag Mahale, Minas P. Economides, Ying Jiang, Anna S. Lok Tags: Viral Hepatitis Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Hematology | Hepatitis | Hepatitis C | Internal Medicine | Liver | Rituxan | Study | Treanda | Urology & Nephrology